MYX2470
/ Myricx Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
July 09, 2024
Francis Crick and ICL spinout raises £90m to clinically develop cancer treatments
(PharmaTimes)
- "The Francis Crick Institute and Imperial College London (ICL) cancer therapy spinout, Myricx Bio, has raised £90m in series A financing to advance its novel cancer treatments into clinical development...The investment will help to develop the company’s therapies to treat a range of different tumour types, including breast, lung and colorectal cancer, to advance into clinical testing...The spinout is focused on the discovery and development of a novel class of payloads for antibody-drug conjugates..."
Financing • Breast Cancer • Colorectal Cancer • Lung Cancer
November 21, 2023
Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics
(GlobeNewswire)
- "Myricx Bio...today announce that they have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on WuXi Bio’s integrated technology platforms. Under the terms of the agreement, Myricx will develop the antibody into a first-in-class ADC based on its NMTi payload platform...including microtubule and topoisomerase inhibitors. Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumours. WuXi Bio will receive an upfront payment and will be eligible for development and commercialisation milestone payments, as well as royalties on net sales."
Licensing / partnership • Solid Tumor
October 17, 2023
Myricx Bio to Present Preclinical Data Validating NMTi as a Novel ADC Payload Class
(GlobeNewswire)
- "Myricx Bio...is presenting preclinical in vivo efficacy data for its NMTi-ADC platform and pipeline at the 14th Annual World ADC Event, San Diego, California, held from October 16-19, 2023....In the poster presentation Myricx reported data for three NMTi-ADCs in its pipeline. These comprise B7-H3-NMTi, TROP2-NMTi, and HER2-NMTi. B7-H3-NMTi demonstrated complete and durable tumour regressions in multiple models of aggressive prostate cancer refractory to Topo1i-based ADCs....TROP2-NMTi also demonstrated complete and durable tumour regressions in breast cancer models refractory to Topo1i-based ADCs; including the ability to regress large and established tumours that had prior exposure to a Topo1i-based ADC. HER2-NMTi demonstrated complete efficacy, and an encouraging tolerability profile in rodents and non-human primates."
Preclinical • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
1 to 3
Of
3
Go to page
1